GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sailong Pharmaceutical Group Co Ltd (SZSE:002898) » Definitions » Capex-to-Revenue

Sailong Pharmaceutical Group Co (SZSE:002898) Capex-to-Revenue : 0.06 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Sailong Pharmaceutical Group Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Sailong Pharmaceutical Group Co's Capital Expenditure for the three months ended in Mar. 2025 was ¥-2.96 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥54.09 Mil.

Hence, Sailong Pharmaceutical Group Co's Capex-to-Revenue for the three months ended in Mar. 2025 was 0.06.


Sailong Pharmaceutical Group Co Capex-to-Revenue Historical Data

The historical data trend for Sailong Pharmaceutical Group Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sailong Pharmaceutical Group Co Capex-to-Revenue Chart

Sailong Pharmaceutical Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.13 0.09 0.10 0.13

Sailong Pharmaceutical Group Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.06 0.11 0.37 0.06

Competitive Comparison of Sailong Pharmaceutical Group Co's Capex-to-Revenue

For the Biotechnology subindustry, Sailong Pharmaceutical Group Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sailong Pharmaceutical Group Co's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sailong Pharmaceutical Group Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sailong Pharmaceutical Group Co's Capex-to-Revenue falls into.


;
;

Sailong Pharmaceutical Group Co Capex-to-Revenue Calculation

Sailong Pharmaceutical Group Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-34.667) / 263.567
=0.13

Sailong Pharmaceutical Group Co's Capex-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.963) / 54.087
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sailong Pharmaceutical Group Co  (SZSE:002898) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Sailong Pharmaceutical Group Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sailong Pharmaceutical Group Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sailong Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
No. 47, Haibin South Road, 2nd Floor, Everbright International Trade Center, Guangdong Province, Zhuhai, CHN, 519015
Sailong Pharmaceutical Group Co Ltd is a pharmaceutical company. It is mainly engaged in the development, production, marketing and technical services of pharmaceuticals. The company's products are mainly concentrated in the fields of the nervous system, cardiovascular and digestive system. The product range includes monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others.
Executives
Tang Lin Director
Long Zhi Xiang Director
Deng Yong Jun Supervisors
Zhou Bei Supervisors
Li Jian Feng Directors, executives

Sailong Pharmaceutical Group Co Headlines

No Headlines